Clover Health Investments Financials - Benzinga

Clover Health Investments Corp

CLOVNASDAQ

Trade with Public

Trade with Public

$4.57

-0.1-2.14%

al cierre: Sep 23, 5:00 PM EST

$4.55

-0.02-0.44%

After hour: 7:52 PM EST

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

Clover Health Investments Financials

Clover Health Investments (CLOV) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Clover Health Investments Raises FY2026 Sales Guidance from $2.810B-$2.920B to $2.920B-$3.000B vs $2.910B Est

Clover Health Investments (NASDAQ:CLOV) raises FY2026 sales outlook from $2.810 billion-$2.920 billion to $2.920 billion-$3.000 billion vs $2.910 billion estimate.

Benzinga Newsdesk

PRO
Clover Health Investments Q2 EPS $0.05 Beats $0.03 Estimate, Sales $743.167M Beat $728.267M Estimate

Clover Health Investments (NASDAQ:CLOV) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.03 by 66.67 percent. This is a 350 percent increase over losses of $(0.02) per share

Benzinga Newsdesk

Jim Cramer Won't Recommend Mortgage Stocks Because 'I Never Know What They Really Own' — But He Loves Intel's 'Burgeoning Packaging Division'

Cramer criticizes Clover Health's quarterly results, recommends Amkor for semiconductor packaging, and expresses caution over mortgage stocks.

Avi Kapoor

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Clover Health Investments Affirms FY2026 Sales Guidance of $2.810B-$2.920B vs $2.878B Est

Clover Health Investments (NASDAQ:CLOV) affirms FY2026 sales outlook from $2.810 billion-$2.920 billion to $2.810 billion-$2.920 billion vs $2.878 billion estimate.

Benzinga Newsdesk

PRO
Clover Health Investments Q1 EPS $0.05 Beats $0.03 Estimate, Sales $749.200M Beat $714.893M Estimate

Clover Health Investments (NASDAQ:CLOV) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.03 by 66.67 percent. The company reported quarterly sales of $749.200 million which

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved